Shanghai Aurefluidics Technology Co., Ltd.focuses on developing next-generation intelligent microfluidic products with proprietary smart MEMS chip design technology. Leveraging an 8-inch MEMS production line, the company offers design, manufacturing, testing, and service capabilities. Its core technologies include CMOS-MEMS inkjet printing chips, microfluidic design, cell printing, temperature control, and system integration, which are applied in drug development, diagnostics, and treatment. Aurefluidics Technology aims to provide high-performance, reliable microfluidic products for bio-printing, industrial, and consumer applications, delivering comprehensive printing solutions.
SeqMatic
SeqMatic is an experienced OMICS SERVICES LABORATORY offering full and partial NGS workflow services for DNA, RNA, Single Cell, Epigenetics, Spatial, Proteomics, Histology, and Bioinformatics (primary, secondary, tertiary). Our specialized assays include micro and small RNA workflows to detect cancer triggers, & multi-omics approaches to better characterize the tumor microenvironment. We are introducing a new sample enrichment service designed specifically for FFPE solid tumor samples with low tumor content. This unique workflow combines high-precision masking with AI-driven digital pathology to enable automated enrichment of anatomically defined regions of interest (ROIs). Visit our booth to see data demonstrating our ability to accurately locate, isolate, separate, and consolidate pure tumor tissue from FFPE blocks or slides—and to generate high-quality NGS data from samples that would otherwise fail. Looking for a CLIA/CAP lab partner to validate and run your custom NGS assay as an LDT? SeqMatic offers full or partial wet-lab onboarding and validation, dry-lab support as needed, and process optimization to improve assay performance while reducing turnaround time and cost. We support batch sizes ranging from a handful of samples to thousands per week. All work is performed in our CLIA/CAP-certified laboratory in Fremont, CA, and we are 100% BIOSECURE Act compliant.
SeqOne
SeqOne is a leading European provider of AI-powered software for next-generation sequencing (NGS) data analysis in oncology and rare diseases. Its cloud-based platform transforms complex genomic data into fast, precise, and actionable insights, supporting molecular labs in delivering life-saving diagnoses and treatments. The SeqOne Platform is CE-IVD Class C certified under HIPAA as an in vitro diagnostic medical device. Driven by the vision of personalized medicine for every patient, everywhere, SeqOne is scaling the future of genomic medicine—one lab at a time. The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club. | SeqOne is a leading European provider of AI-powered software for next-generation sequencing (NGS) data analysis in oncology and rare diseases. Its cloud-based platform transforms complex genomic data into fast, precise, and actionable insights, supporting molecular labs in delivering life-saving diagnoses and treatments. The SeqOne Platform is CE-IVD Class C certified under IVDR as an in vitro diagnostic medical device. Driven by the vision of personalized medicine for every patient, everywhere, SeqOne is scaling the future of genomic medicine—one lab at a time. The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club.
SensID, a Microbiologics Company
“Microbiologics helps cancer researchers and diagnostic developers trust every result with high-quality reference materials from our SensID portfolio. SensID products are designed to reflect real clinical samples and support assay development, validation, and ongoing quality control across molecular oncology testing. Our portfolio spans key material types, including: human genomic DNA (gDNA) controls, cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) for liquid biopsy assays, human-tech plasma for full workflow controls, and formalin-fixed paraffin-embedded (FFPE) standards for solid tumor applications. Well-known examples include EGFR-Multiplex cfDNA sets for mutation detection across allele frequencies, ESR1 & PIK3CA reference sets for precision liquid biopsy quality control, and MSI/MSS FFPE reference materials to mimic patient samples in microsatellite instability testing. Researchers use SensID products to validate NGS and PCR assays, benchmark instrument performance, and monitor routine operations with confidence. Backed by deep genomic characterization and consistent lot performance, SensID materials help you advance oncology workflows with clarity and reliability.”
Seer
At Seer, we develop innovative solutions that act as a gateway to the proteome. Our goal is to empower the scientific community with tools to achieve exceptional scientific outcomes. We do this by removing the technological barriers that stand between breakthrough ideas and the information that can make them a reality. Seer’s Proteograph Product Suite provides the only proteomics workflow that enables deep, unbiased proteomic content at scale, at the peptide level. With the Proteograph Product Suite, we are making the proteome even more accessible, not just to the proteomics community, but also to genomics researchers, who are eager to deeply characterize genomic variants with functional proteomic information, deepening their biological insights. Adding deep, unbiased, peptide-level proteomics data to research studies can provide unrivaled insight into biology, disease progression, and targets for precision diagnostics and therapeutics. We look forward to meeting you at AACR. | Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.
Scientist.com
Scientist.com is the world’s largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies. Scientist.com operates private marketplaces for most of the world’s major pharmaceutical companies and the US NIH. Visit scientist.com to learn more.
SBDX
Human tissue biobank. We supply high quality FFPE tissues for research, controls, IHC validation and pharma development. Our inventory consists of malignant tumors of all types, normal tissue, diseased tissue and tissues with known IHC results, genetic mutations and other specific criteria to support your projects.
Sapient
Sapient is a leader in multi-omics data generation and insight delivery, providing bespoke services for proteomics, metabolomics, and lipidomics that enable biopharma sponsors to go beyond the genome to accelerate precision drug development. Utilizing cutting-edge, high throughput mass spectrometry, we make nontargeted and targeted measurements to capture thousands of dynamic biomarkers – including proteins, metabolites, and lipids – per sample, across thousands of samples at a time. We pair this with advanced biocomputational frameworks enabling comprehensive biomarker-phenotype mapping for discovery of robust biomarkers, drug targets, and clinical signatures of drug response. Aided by our DynamiQ™ Insights Engine — a longitudinal database of integrated multi-omics and real-world data collected in tens of thousands of samples — we can support rapid drug target identification, biomarker discovery and validation, and translational insights across all stages of drug development, including clinical trials.
Sampled
Sampled is a fully integrated laboratory and biorepository with industry-leading storage, sample management, multiomics, cellular services, and custom clinical kitting. Founded in 1999 as RUCDR at Rutgers University, Sampled operates facilities in the US and UK and is CAP accredited and CLIA licensed. Sampled is committed to providing the highest quality sample storage, processing, and analysis services that enable researchers to make new discoveries and advance human health. When combined with state-of-the-art biobanking facilities, these capabilities provide comprehensive scientific solutions that speed time to quality data. | Sampled is a next-generation laboratory that unlocks the valuable data in any biological sample. Through our integrated Sampled SMART Lab services, we can Store, Manage, Analyze, Research and Transport biological materials, offering partners a seamless solution for all research samples. Our vision is a world where we make it faster and easier for health innovators to improve human health, with a mission to be the Sampled SMART Lab behind every transformative health innovation. Sampled headquartered in Piscataway, N.J. with labs across the US and Europe and partner labs in the Netherlands, China and Australia.
SAGA Diagnostics
SAGA Diagnostics® is redefining the early detection of molecular residual disease (MRD), empowering treatment decisions with greater insight and confidence. Pathlight™, the company’s flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that is available for commercial use in the U.S. for patients with breast and colorectal cancers. SAGA is partnering with pharmaceutical and biotechnology companies, as well as commercial entities, to support early through late-stage cancer development programs across a range of cancer types.